Literature DB >> 2121266

In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity.

K J Pasi1, F G Hill.   

Abstract

Seven factor VIII concentrates of varying purity (specific activity 0.67-10 units factor VIII procoagulant activity (VIII: C)/mg protein) have been examined over a range of concentrations (0.5-0.005 u/ml factor VIII) to establish their effect on in vitro monocyte phagocytic function. All these products inhibited monocyte phagocytic function, but the monoclonally purified product tested was significantly less inhibitory than the others (P less than 0.05). The degree of inhibition observed was independent of the virus inactivation method used to increase product safety. However, comparison of these products of differing purity from the same manufacturer showed that the inhibitory effect decreased as product purity increased. In vivo studies of monocyte function following infusion of two of these factor VIII concentrates demonstrated inhibition of circulating monocytes. The possible role of product purity in modulating immune responses in haemophiliacs is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121266     DOI: 10.1111/j.1365-2141.1990.tb07841.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.

Authors:  M C Poon
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

2.  Concurrent lymphoma and hemophilia B in a pediatric patient: A case report.

Authors:  Guoyan Lu; Lina Qiao; Deyuan Li; Zhongqiang Liu; Fumin Zhao; Dan Yu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  A rare case of acute lymphoblastic leukaemia with hemophilia A.

Authors:  Rahul Sinha; Kirandeep Sodhi; Biju John; Daljit Singh
Journal:  Ital J Pediatr       Date:  2009-12-11       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.